More on BBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $68.12 |
|
|||
| Open | $67.69 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $68.86 | ||||
| Day Low | $67.02 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 2,403,348 | ||||
- BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
- BridgeBio Pharma (BBIO) PT Lowered to $87 at Morgan Stanley
- BridgeBio Pharma (BBIO) PT Raised to $120 at Piper Sandler
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Pharma (BBIO) PT Raised to $92 at UBS
- H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- Form 8-K BridgeBio Pharma, Inc. For: Oct 06
- Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print'
- Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
- BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial
Entities mentioned with BBIO
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
